Skip to Navigation Skip to Search Skip to Content
Search All Centers

Comparing CAR-NK and CAR T-Cell Therapies

Read Transcript
View next

Published on October 28, 2020

How Do Chimeric Antigen Receptor (CAR) Therapies Differ?

Chimeric Antigen Receptor therapy may provide an "off the shelf" option to the genetic-specific CAR T-cell therapy. While CAR T-cell therapy is more well-known and studied, there are challenges to the manufacturing of CAR T that does not exist with CAR-NK. This may prove to be a game-changer for blood cancer patients who do not have the time to wait for a CAR T-cell donor or for their own cells to be engineered for treatment.

Dr. Katy Rezvani, Chief, Section of Cellular Therapy, Department of Stem Cell Transplantation & Cellular Therapy, MD Anderson Cancer Center joins Patient Power Co-founder Andrew Schorr to explain the difference between the two new cell therapies and what this innovation means for ALL, CLL, and NHL patients. 

Featuring

Transcript | Comparing CAR-NK and CAR T-Cell Therapies

Andrew Schorr:
Hello and welcome to Patient Power. I'm Andrew Schorr. We're having a discussion with Dr. Katy Rezvani, who is a researcher at MD Anderson in Houston, really looking at what could be next in treatment for people with a number of blood cancers; chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) and maybe other cancers. We're talking about CAR natural killer cell treatment. Now doctor, many patients have been hearing about either experimentally or approved chimeric antigen receptor T-cell therapy. How is CAR-NK therapy different? And what advantages might it have if it works out?

Are There Advantages to CAR-NK Over CAR T-Cell Therapy?

Dr. Rezvani:
At least in my mind, potentially the advantages could be the safety profile of CAR-NK cells. Of course, we have treated only a small number of patients and our follow-up is certainly shorter than follow-ups with patients who have been treated with CAR T-cells. But in this small group of patients, at least, we haven't seen the toxicities that had been described with the CAR T-cells, such as the cytokine storm or the neurological complications. And none of our patients for instance required any support on the intensive care unit, which many patients with CAR T-cells do.

Now, the other unique aspect of natural killer cells is unlike T-cells, natural killer cells when taken from source that is unrelated to the patient, will not cause graft versus host disease. So, natural killer cells do not have the capability to pose graft versus host disease. It's to do with their biology. And this opens the way then to go and make banks of natural killer cells from a donor that could be completely unrelated to a patient and to make these biobanks themselves, that then can be used to treat patients pretty much off the shelf.

How are CAR T-Cells Made?

Currently, the way CAR T-cells are made is, at least for the commercially available CAR T-cells, you have to collect the blood from the patient. You have to manufacture the CAR T-cells and then give it back to the patient. And that brings two major points that we need to bear in mind. One is the cost and the logistics and also with some patients who have very aggressive disease, they may not have the four weeks or six weeks that is needed.

If we are capable, if we're able to have an off the shelf product so that the patient comes into your office and without any consideration for matching, without any consideration for growing, you have these cells frozen, they're sitting in a biobank and you can thaw and infuse that would make the strategy obviously much more attractive and also cheaper because if you can make multiple products from one donor, you bring the cost of manufacturing and the cost of therapy.

Will CAR-NK Cell Therapy Become Widely Available?

You need to have a source of cell. You need to have a way of reliably freezing the cells so that you're certain that when you thaw the cells, they are as functional and as effective as the fresh counterpart. And that's what we are working on at the moment. In the study that we've been doing so far, the CAR-NK cells are actually manufactured fresh and given to the patients fresh. We've so far been using one umbilical cord unit to manufacture CAR-NK cells for one patient and to infuse into that patient. But our next steps are now to manufacture multiple doses of CAR-NK cells that then we can freeze and to infuse into patients.

How do Chimeric Antigen Receptor (CAR) Therapies and Stem Cell Transplants Compare?

Andrew Schorr:
One last question about this. Do you think that this chimeric antigen receptor therapy T-cell or NK cell will kind of supersede stem cell transplant?

Dr. Rezvani:
I think what is happening is that the field of stem cell transplantation is evolving. And for certain types of cancers, it is very possible that CAR T-cells will, or CAR-NK cells will supersede allogeneic stem cell transplantation. For other types of cancers, probably stem cell transplantation will stay with us for a while longer. Ultimately, I think the goal is to be able to provide our patients with the most effective therapy with the least amount of toxicity. And that's where I'm hoping and I pray that we will be heading towards. At least for lymphomas and the lymphoid malignancies, I really do believe that the field of stem cell transplantation is already in the evolution of going towards cell therapy.

Andrew Schorr:
Dr. Katy Rezvani, thank you for all you do as a researcher and really pioneering work and for being with us today. We wish you well with your research.

Dr. Rezvani:
Thank you.

Andrew Schorr:
I'm Andrew Schorr. Knowledge can be the best medicine of all.


Recommended Programs:

View next